Advertisement
Screener

Nkarta, Inc. (NKTX) Increase Decrease In Operating Lease Liability

2.8 / 5 stars · 68/120 Roast Me

Nkarta, Inc. Increase Decrease In Operating Lease Liability

Nkarta, Inc. (NKTX) reported Increase Decrease In Operating Lease Liability of -$2.88 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.

Financial Statements › Cash Flow › Operating Activities

us-gaap:IncreaseDecreaseInOperatingLeaseLiability · last filed 2026-08-10

  • Nkarta, Inc. increase decrease in operating lease liability for the quarter ending 2026-06-30 was -$1.46M.
  • Nkarta, Inc. increase decrease in operating lease liability for the quarter ending 2026-03-31 was -$1.42M.
  • Nkarta, Inc. increase decrease in operating lease liability for the quarter ending 2025-12-31 was -$1.37M.
  • Nkarta, Inc. increase decrease in operating lease liability for the quarter ending 2025-09-30 was -$1.91M.
  • Nkarta, Inc. increase decrease in operating lease liability for fiscal 2025 was -$5.01M.
  • Nkarta, Inc. increase decrease in operating lease liability for fiscal 2024 was -$6.42M, a 228.68% decline from fiscal 2023.
  • Nkarta, Inc. increase decrease in operating lease liability for fiscal 2023 was $4.99M, a 84.64% decline from fiscal 2022.
  • Nkarta, Inc. increase decrease in operating lease liability for fiscal 2022 was $32.47M.
Period endIncrease Decrease In Operating Lease Liability 3 monthIncrease Decrease In Operating Lease Liability 3 month as first filedIncrease Decrease In Operating Lease Liability 6 monthIncrease Decrease In Operating Lease Liability 6 month as first filedIncrease Decrease In Operating Lease Liability 9 monthIncrease Decrease In Operating Lease Liability 12 month
2026-06-30-$1.46M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10
-$2.88M
10-Q · filed 2026-08-10
-$4.25M
derived: sum of 3 quarters · filed 2026-08-10
-$6.16M
derived: sum of 4 quarters · filed 2026-08-10
2026-03-31-$1.42M
10-Q · filed 2026-05-12
-$2.79M
derived: sum of 2 quarters · filed 2026-05-12
-$4.70M
derived: sum of 3 quarters · filed 2026-05-12
-$5.07M
derived: sum of 4 quarters · filed 2026-08-10
2025-12-31-$1.37M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25
-$3.28M
derived: sum of 2 quarters · filed 2026-03-25
-$3.65M
derived: sum of 3 quarters · filed 2026-08-10
-$5.01M
10-K · filed 2026-03-25
2025-09-30-$1.91M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10
-$2.28M
derived: sum of 2 quarters · filed 2026-08-10
-$3.64M
10-Q · filed 2025-11-10
-$6.59M
derived: sum of 4 quarters · filed 2026-08-10
2025-06-30-$369.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10
-$1.73M
10-Q · filed 2026-08-10
-$4.68M
derived: sum of 3 quarters · filed 2026-08-10
-$4.80M
derived: sum of 4 quarters · filed 2026-08-10
2025-03-31-$1.36M
10-Q · filed 2026-05-12
-$4.31M
derived: sum of 2 quarters · filed 2026-05-12
-$4.43M
derived: sum of 3 quarters · filed 2026-05-12
-$6.61M
derived: sum of 4 quarters · filed 2026-05-12
2024-12-31-$2.95M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25
-$3.07M
derived: sum of 2 quarters · filed 2026-03-25
-$5.25M
derived: sum of 3 quarters · filed 2026-03-25
-$6.42M
10-K · filed 2026-03-25
2024-09-30-$124.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10
-$2.31M
derived: sum of 2 quarters · filed 2025-11-10
-$3.47M
10-Q · filed 2025-11-10
-$4.59M
derived: sum of 4 quarters · filed 2025-11-10
2024-06-30-$2.18M
derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12
-$3.35M
10-Q · filed 2025-08-12
-$4.47M
derived: sum of 3 quarters · filed 2025-08-12
-$5.50M
derived: sum of 4 quarters · filed 2025-08-12
2024-03-31-$1.16M
10-Q · filed 2025-05-14
-$2.29M
derived: sum of 2 quarters · filed 2025-05-14
-$3.32M
derived: sum of 3 quarters · filed 2025-05-14
-$4.17M
derived: sum of 4 quarters · filed 2025-05-14
2023-12-31-$1.13M
derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-26
-$2.16M
derived: sum of 2 quarters · filed 2025-03-26
-$3.01M
derived: sum of 3 quarters · filed 2025-03-26
$4.99M
10-K · filed 2025-03-26
2023-09-30-$1.03M
derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07
-$1.88M
derived: sum of 2 quarters · filed 2024-11-07
$6.11M
10-Q · filed 2024-11-07
$27.14M
derived: sum of 4 quarters · filed 2024-11-07
2023-06-30-$849.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13
$7.14M
10-Q · filed 2024-08-13
$28.17M
derived: sum of 3 quarters · filed 2024-08-13
$35.96M
derived: sum of 4 quarters · filed 2024-08-13
2023-03-31$7.99M
10-Q · filed 2024-05-09
$29.02M
derived: sum of 2 quarters · filed 2024-05-09
$36.81M
derived: sum of 3 quarters · filed 2024-05-09
$38.85M
derived: sum of 4 quarters · filed 2024-05-09
2022-12-31$21.02M
derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21
$28.82M
derived: sum of 2 quarters · filed 2024-03-21
$30.86M
derived: sum of 3 quarters · filed 2024-03-21
$32.47M
10-K · filed 2024-03-21
2022-09-30$7.80M
derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09
$9.83M
derived: sum of 2 quarters · filed 2023-11-09
$11.45M
10-Q · filed 2023-11-09
2022-06-30$2.04M
derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10
$3.65M
10-Q · filed 2023-08-10
$726.00K
10-Q · filed 2022-08-11
2022-03-31$1.61M
10-Q · filed 2023-05-11
$295.00K
10-Q · filed 2022-05-12

Similar stocks

Stock NameCountryMarket CapPE Ratio
ORAMED PHARMACEUTICALS INC. (ORMP)$0.199B1.13
Zentalis Pharmaceuticals, Inc. (ZNTL)United States$0.196B-2.48
Foghorn Therapeutics Inc. (FHTX)United States$0.213B-4.43
Eledon Pharmaceuticals, Inc. (ELDN)United States$0.219B-3.23
Whitehawk Therapeutics, Inc. (WHWK)United States$0.221B
Fortress Biotech, Inc. (FBIO)United States$0.188B0.91
ALX ONCOLOGY HOLDINGS INC (ALXO)United States$0.187B-3.52
PepGen Inc. (PEPG)United States$0.186B-1.73
AN2 Therapeutics, Inc. (ANTX)United States$0.185B-4.84
NATURES SUNSHINE PRODUCTS INC (NATR)United States$0.228B20.51